HR7936

1) What happened and its current status: On 2026-03-16, Rep. Baird (R-IN) introduced HR7936, the Bioindustrial Scale-Up for Supply Chains and Energy Resiliency Act. The bill was referred to the House Committee on Science, Space, and Technology. It has 6 cosponsors and is in early stage — no hearings, markups, or floor votes have occurred. The bill is not yet law and faces a long legislative path. 2) The money trail — authorization vs. appropriation: HR7936 authorizes DOE to establish technology maturation facilities for scaling bioindustrial manufacturing, but it does NOT appropriate any funding. Authorization sets policy and spending ceilings; actual dollars require a separate appropriations bill. Without an appropriation, no facilities will be built, no grants issued, and no contracts awarded. The bill explicitly amends existing law (Energy Policy Act of 2005) but provides no dollar figures. 3) Structural winners and losers: There are no immediate winners or losers. The bill positions ADM (Archer-Daniels-Midland) as a feedstock supplier and DD (DuPont de Nemours) as a bioprocess developer for potential future DOE programs. However, because no funds are authorized, neither company can expect any near-term revenue. Pure-play biomanufacturing or industrial biotech companies (e.g., $GINK, $AMRS if still public) could be long-term beneficiaries if appropriations are passed, but this is speculative. 4) Market data analysis: ADM is currently trading at $74.27, up 6.05% in 7 days, approaching its 52-week high of $74.89. This price action is likely driven by agricultural commodity price movements or earnings expectations rather than HR7936. DD is at $44.62, down 3.77% in 7 days, also reflecting company-specific or sector trends. Neither stock's recent movement correlates with this bill's introduction date (March 16) or any subsequent action. 5) Timeline: The bill is at the earliest possible stage. It must pass committee in the House, then the full House, then an identical Senate version (no companion bill exists), then be signed into law. Even if enacted, a separate appropriations bill must pass to fund the programs. Given the 119th Congress's calendar (ends Jan 2027) and the lack of committee markup this late in the session, passage is uncertain.